Last reviewed · How we verify
Eutirox®
At a glance
| Generic name | Eutirox® |
|---|---|
| Sponsor | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH) (PHASE4)
- Effect of Photobiomodulation Therapy in Patients With Hashimoto's Thyroiditis (NA)
- Effects of Low-Level Laser Therapy on Oxidative Stress Levels (NA)
- Levothyroxine-sodium Bioequivalence Trial With Oral Single Dose Administration (PHASE1)
- A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants (PHASE2)
- Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg (PHASE1)
- Fasting Study of Levothyroxine Sodium Tablets 300 mcg to Synthroid® Tablets 300 mcg (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: